These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11361209)

  • 1. Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.
    Singh G
    J Rheumatol; 2001 May; 28(5):1174-9. PubMed ID: 11361209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System).
    Fries JF
    J Rheumatol; 1995 May; 22(5):995-7. PubMed ID: 8587097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center.
    Lindquist M; Edwards IR
    J Rheumatol; 2001 May; 28(5):1180-7. PubMed ID: 11361210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The need for a post-marketing surveillance program in Israel.
    Shemer J
    Isr Med Assoc J; 1999 Oct; 1(2):98-9. PubMed ID: 10731306
    [No Abstract]   [Full Text] [Related]  

  • 6. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New drugs require nw follow-up surveillance].
    Feltelius N; Lindblad S
    Lakartidningen; 2001 Feb; 98(9):951-3. PubMed ID: 11292975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
    Welch V; Singh G; Strand V; Fries J; Boers M; Ramey D; Day RO; Brooks P; Tugwell P; Clinch J; Kristjansson B
    J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 13. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
    Takeuchi T; Tatsuki Y; Nogami Y; Ishiguro N; Tanaka Y; Yamanaka H; Kamatani N; Harigai M; Ryu J; Inoue K; Kondo H; Inokuma S; Ochi T; Koike T
    Ann Rheum Dis; 2008 Feb; 67(2):189-94. PubMed ID: 17644554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 16. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Post-marketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1201; author reply 1202. PubMed ID: 8692358
    [No Abstract]   [Full Text] [Related]  

  • 18. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.